Single-Dose gene therapy aims to reprogram immune cells against tough leukemia
NCT ID NCT07696481
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This early-phase trial tests a single injection of PID23, a gene therapy that instructs a patient's own immune cells to attack leukemia cells. It targets three markers (CD19, BCMA, and CD70) on cancer cells. The study enrolls up to 18 people aged 3 to 75 with relapsed or refractory acute leukemia who have few treatment options. The main goals are to check safety and find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PID23 Injection (in vivo CAR-T therapy)
- What this could lead to
- If successful, this could offer a new treatment option for people with hard-to-treat acute leukemia who have few alternatives.
- What could go wrong
- This is a very early, small study (up to 18 people) focused on safety. The therapy may not work, and side effects like cytokine release syndrome or nerve problems are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hematology, Zhujiang Hospital, Southern Medical University
Guangzhou, Guangdong, 510282, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a menin-blocking drug outsmart stubborn leukemia?
- New pill targets rare gene mutation in Hard-to-Treat blood cancers
- New hope for elderly blood cancer patients: experimental transplant prep shows promise
- New hope for tough blood cancers? early trial of CG009301 begins
- New hope for tough AML: targeted pill plus chemo combo tested